When to Choose GLP-Squared Over Single-Agent Semaglutide Patients who plateau on semaglutide alone or experience inadequate weight loss after 12 weeks often benefit from tirzepatide, a dual GIP and GLP-1 receptor agonist with stronger appetite suppression
Gallo A, Le Goff W, Santos RD, et al
They also looked closely at different patient characteristics, such as age, gender, body mass index (BMI) and blood test results, to better understand patient groups
Multiple reviews reference early Croatian clinical trials involving inflammatory bowel disease patients
It used a ShapiroWilk test to assess normality and an F-test to assess homoscedasticity, and attempted log-transformation to resolve any lack thereof 40
Patients often notice improvements early on, with key milestones including: Initial Response Many patients experience a boost in energy and mental clarity within the first few sessions